Methods for treating TWEAK-related conditions
View Patent ↗The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.
1. A method for treating non-inflammatory dilated cardiomyopathy, in a human subject comprising the step of administering to the subject a therapeutically effective amount of an antibody that binds human TWEAK (an anti-TWEAK antibody) or antigen-binding fragment thereof.
2. The method of claim 1 , wherein the antibody is human or humanized.
3. The method of claim 1 , wherein the antibody is monoclonal.
4. The method of claim 1 , wherein the antibody is chimeric.
5. The method of claim 1 , wherein the antibody is full length.
6. The method of claim 1 , wherein the antibody is an antigen-binding fragment.
7. The method of claim 1 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is administered to the subject via a route selected from the group consisting of: injection, transmucosal, oral, inhalation, ocular, rectal, stent implantation, topical, parenteral, long acting implantation, sustained release, and aural routes.
8. The method of claim 7 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is administered to the subject via a parenteral route.
9. The method of claim 1 , wherein said anti-TWEAK antibody or antigen-binding fragment thereof is in a delivery formulation selected from the group consisting of: tablets, pills, liposomes, granules, spheres, dragees, capsules, liquids, gels, syrups, slurries, suspensions, stent coatings and sustained-release formulations.